Kymab, the Cambridge-based antibodies-to-medicines company, features in the top ten of The Sunday Times Tech Track ‘Ones to Watch’ 2015.
The ranking, published on Sunday 6 September 2015, recognises Kymab’s potential for rapid future sales growth and increasing international presence. The Sunday Times Hiscox Tech Track 100 ranks Britain’s 100 fastest-growing private companies, based on sales over three years.
With investment from Bill & Melinda Gates Foundation, Malin Corporation plc, the Wellcome Trust, and Woodford Patient Capital Trust plc, Kymab is using its unique antibody development platform in therapeutic development and vaccine discovery. Its current targets include autoimmune disease and cancers, as well as infectious disease, such as HIV and malaria.
"I am delighted and very proud that the growth Kymab has made has been recognised by The Sunday Times Tech Track, a barometer for success," said Professor Allan Bradley, Chief Technical Officer, who founded Kymab in 2009. "The healthcare and research partners we work with know that Kymab is achieving remarkable results; our investors know that we are performing extremely well."
"To be recognised for our business performance by inclusion in this highly regarded table is a significant achievement for our Company,” added Dr David Chiswell Chairman and interim CEO.
The full listing is published with the Business section in The Sunday Times and in the digital edition.
The recognition follows Kymab’s nomination in June 2015 for the Emerging Star award at the London Stock Exchange techMARK mediscience annual event which celebrates excellence within the life-sciences sector.
Notes to Editors
Kymab is a biopharmaceutical company working with leading partners to develop therapies and to drive vaccine discovery using its unique platform to deliver human antibodies. Kymab’s technology assures the highest likelihood of discovering best-in-class drug and vaccine candidates.
Kymab’s is using its efficient and nimble technology to develop products in challenging and important areas including autoimmune disease, cancers, and infectious disease, such as HIV and malaria.
Under a management team with a proven track record in antibody research, cell engineering and drug discovery and development, Kymab has raised more than $120m in equity funding from partners including Bill & Melinda Gates Foundation, the Wellcome Trust, Malin Corporation plc and the Woodford Patient Capital Trust plc.